Gut microbiome: A possible common therapeutic target for treatment of atherosclerosis and cancer

Wei-Kai Wu,Ekaterina A Ivanova,Alexander N Orekhov,Ekaterina A. Ivanova,Alexander N. Orekhov

DOI: https://doi.org/10.1016/j.semcancer.2020.06.017

IF: 17.012

2021-05-01

Seminars in Cancer Biology

Abstract:<p>Human gut microbiota is a dynamic and variable system that can change over time and in response to different diets and treatments. There is currently no doubt that gut microbiota can provide interesting therapeutic opportunities, since it can metabolize biologically active molecules, drugs, and their precursors, and control their bioavailability. Moreover, it can produce both beneficial and dangerous metabolites that influence host's health. In this review, we summarize the current knowledge on the involvement of gut microbiota in two chronic human pathologies that represent the greatest challenges of modern medicine: atherosclerosis and cancer. Interesting parallels are observed between the mechanisms and possible treatment approaches of these pathologies. Some of the common effects of therapeutic agents targeting both pathologies, such as anti-inflammatory activity, are partially mediated by the gut microbiota. We will discuss the effects of common drugs (metformin, statins and aspirin) and various nutraceuticals on gut microbiota and outline the pathways of microbial involvement in mediating the pleiotropic beneficial effects of these agents in atherosclerosis and cancer.</p>

oncology

What problem does this paper attempt to address?

The paper attempts to address the question of whether the gut microbiome can serve as a common therapeutic target for the treatment of atherosclerosis and cancer. Specifically, the paper summarizes current knowledge on the role of the gut microbiome in atherosclerosis and cancer, and discusses the shared mechanisms and potential therapeutic approaches involving the gut microbiome in these diseases. Additionally, the paper explores the impact of common drugs (such as metformin, statins, and aspirin) and various nutritional supplements on the gut microbiome, and how these effects may mediate the pleiotropic beneficial effects of these drugs in atherosclerosis and cancer.

In short, the paper aims to identify potential common therapeutic strategies by studying the role of the gut microbiome in two chronic diseases.